Why the study?
Cancer survivors face an elevated risk of CVD mortality, making the identification of biomarkers associated with CVDs in this growing population vital.
Does the Glycated Hemoglobin to High Density Lipoprotein Cholesterol Ratio (GH/HDL-C) predict cardiovascular disease mortality in adult cancer survivors?
Population
3,244 adult cancer survivors from NHANES (1999-2018)
Comparison
Higher vs lower GH/HDL-C ratio levels across age groups
Design
Retrospective cohort study
Follow-up
168 months
Authors
Loading...
May inform CVD risk assessment in cancer survivors; leaves open whether GH/HDL-C predict outcomes prospectively.
Does the Glycated Hemoglobin to High Density Lipoprotein Cholesterol Ratio (GH/HDL-C) predict cardiovascular disease mortality in adult cancer survivors?
The GH/HDL-C ratio is a significant, age-dependent biomarker for predicting cardiovascular mortality risk in adult cancer survivors.
Sun et al. (2025) studied this question.